EP1414845A4 - Sezernierte humanproteine - Google Patents

Sezernierte humanproteine

Info

Publication number
EP1414845A4
EP1414845A4 EP02782476A EP02782476A EP1414845A4 EP 1414845 A4 EP1414845 A4 EP 1414845A4 EP 02782476 A EP02782476 A EP 02782476A EP 02782476 A EP02782476 A EP 02782476A EP 1414845 A4 EP1414845 A4 EP 1414845A4
Authority
EP
European Patent Office
Prior art keywords
secreted proteins
human secreted
human
proteins
secreted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02782476A
Other languages
English (en)
French (fr)
Other versions
EP1414845A2 (de
Inventor
Craig A Rosen
Steven M Ruben
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of EP1414845A2 publication Critical patent/EP1414845A2/de
Publication of EP1414845A4 publication Critical patent/EP1414845A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP02782476A 2001-03-21 2002-03-19 Sezernierte humanproteine Withdrawn EP1414845A4 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US27734001P 2001-03-21 2001-03-21
US277340P 2001-03-21
US30617101P 2001-07-19 2001-07-19
US306171P 2001-07-19
US33128701P 2001-11-13 2001-11-13
US331287P 2001-11-13
PCT/US2002/008124 WO2003004622A2 (en) 2001-03-21 2002-03-19 Human secreted proteins

Publications (2)

Publication Number Publication Date
EP1414845A2 EP1414845A2 (de) 2004-05-06
EP1414845A4 true EP1414845A4 (de) 2009-07-08

Family

ID=27402891

Family Applications (7)

Application Number Title Priority Date Filing Date
EP02749512A Withdrawn EP1381622A2 (de) 2001-03-21 2002-03-19 Sezernierte humanproteine
EP02760994A Withdrawn EP1379132A4 (de) 2001-03-21 2002-03-19 Sezernierte humanproteine
EP02759068A Withdrawn EP1404702A4 (de) 2001-03-21 2002-03-19 Sezernierte humanproteine
EP02782476A Withdrawn EP1414845A4 (de) 2001-03-21 2002-03-19 Sezernierte humanproteine
EP02780789A Withdrawn EP1423134A2 (de) 2001-03-21 2002-03-19 Sezernierte humanproteine
EP02799146A Withdrawn EP1390390A4 (de) 2001-03-21 2002-03-19 Sezernierte humanproteine
EP02723499A Withdrawn EP1379264A4 (de) 2001-03-21 2002-03-19 Sezernierte humanproteine

Family Applications Before (3)

Application Number Title Priority Date Filing Date
EP02749512A Withdrawn EP1381622A2 (de) 2001-03-21 2002-03-19 Sezernierte humanproteine
EP02760994A Withdrawn EP1379132A4 (de) 2001-03-21 2002-03-19 Sezernierte humanproteine
EP02759068A Withdrawn EP1404702A4 (de) 2001-03-21 2002-03-19 Sezernierte humanproteine

Family Applications After (3)

Application Number Title Priority Date Filing Date
EP02780789A Withdrawn EP1423134A2 (de) 2001-03-21 2002-03-19 Sezernierte humanproteine
EP02799146A Withdrawn EP1390390A4 (de) 2001-03-21 2002-03-19 Sezernierte humanproteine
EP02723499A Withdrawn EP1379264A4 (de) 2001-03-21 2002-03-19 Sezernierte humanproteine

Country Status (4)

Country Link
EP (7) EP1381622A2 (de)
AU (6) AU2002354719A1 (de)
CA (7) CA2441840A1 (de)
WO (7) WO2002095010A2 (de)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196164B2 (en) 1997-07-08 2007-03-27 Human Genome Sciences, Inc. Secreted protein HHTLF25
CA2295474A1 (en) 1997-07-08 1999-01-21 Human Genome Sciences, Inc. 123 human secreted proteins
US20030149531A1 (en) 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US20040141975A1 (en) 1998-06-01 2004-07-22 Raitano Arthur B. Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
ES2629442T3 (es) 1998-06-01 2017-08-09 Agensys, Inc. Nuevos antígenos transmembranales en serpentina expresados en cánceres humanos y utilizaciones de los mismos
US20060052321A1 (en) 2002-04-05 2006-03-09 Raitano Arthur B Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
BR0007556A (pt) 1999-01-15 2001-10-23 Biogen Inc Antagonistas de tweak e de receptor de tweak e uso dos mesmos para tratar distúrbios imunológicos
EP1666490A3 (de) * 2000-07-25 2006-11-02 Genentech, Inc. Sekretierte und transmembrane Polypeptide und dafür kodierende Nukleinsäuren
US7335731B2 (en) 2000-07-25 2008-02-26 Genentech, Inc. PRO4332 polypeptides
AU2002243444A1 (en) 2000-10-31 2002-06-24 Diadexus, Inc. Compositions and methods relating to colon specific genes and proteins
US20020111302A1 (en) * 2000-11-30 2002-08-15 Y. Tom Tang Novel nucleic acids and polypeptides
WO2002083921A2 (en) * 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
US7250495B2 (en) 2001-06-20 2007-07-31 Genentech, Inc. PRO20044 polypeptides
ES2532757T3 (es) 2001-09-06 2015-03-31 Agensys, Inc. Ácido nucleico y proteína correspondiente denominados STEAP-1 útiles en el tratamiento y la detección de cáncer
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
CA2463596A1 (en) 2001-10-12 2003-04-24 Yamanouchi Pharmaceutical Co., Ltd. Method of screening cell death inhibitor
WO2003086311A2 (en) 2002-04-09 2003-10-23 Biogen, Inc. Methods for treating tweak-related conditions
AU2003900747A0 (en) * 2003-02-18 2003-03-06 Garvan Institute Of Medical Research Diagnosis and treatment of pancreatic cancer
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
WO2005019258A2 (en) * 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
AU2004275828B2 (en) 2003-09-23 2010-04-29 University Of North Carolina At Chapel Hill Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin K epoxide reductase gene and warfarin dosage
CA2542017A1 (en) * 2003-10-14 2005-05-06 Baxter International, Inc. Vitamin k epoxide recycling polypeptide vkorc1, a therapeutic target of coumarin and their derivatives
US20070269421A1 (en) * 2004-02-03 2007-11-22 Bayer Healthcare Ag Diagnostics and Therapeutics for Diseases Associated with Plasma Glutamate Carboxypeptidase (Pgcp)
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
AU2004319915B9 (en) 2004-04-22 2011-12-22 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
KR101268877B1 (ko) 2004-09-01 2013-05-31 다이나박스 테크놀로지 코퍼레이션 선천성 면역반응 및 자가면역의 억제를 위한 방법 및조성물
WO2006026807A1 (en) * 2004-09-07 2006-03-16 Telethon Institute For Child Health Research Agents for treatment or prevention of an allergic disorder
CA2579705A1 (en) * 2004-09-07 2006-03-16 Telethon Institute For Child Health Research Method of diagnosing and/or predicting the development of an allergic disorder
DK2529619T3 (en) 2005-02-17 2016-01-11 Biogen Ma Inc Treatment of neurological disorders
WO2006089613A1 (en) 2005-02-28 2006-08-31 Baxter International Inc. Recombinant co-expression of vitamin k epoxide reductase subunit 1 to improve vitamin k dependent protein expression
JP2008532544A (ja) 2005-03-15 2008-08-21 ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 活性ビタミンｋ依存性タンパク質を生産するための方法及び組成物
EP1885388B1 (de) 2005-05-10 2013-09-11 Biogen Idec MA Inc. Behandlung und beurteilung von entzündlichen erkrankungen
WO2006138219A2 (en) * 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
GB2470843B (en) * 2005-09-01 2011-04-13 Florey Howard Inst Models and methods for the assessment of potential therapeutic agents for the modulation of NDFIP1-NEDD4 interactions
GB0521488D0 (en) * 2005-10-21 2005-11-30 Ares Trading Sa Integral membrane protein
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
ES2636089T3 (es) 2006-10-27 2017-10-05 Genentech, Inc. Anticuerpos e inmunoconjugados y usos para los mismos
CN101636179B (zh) 2006-11-07 2012-10-10 默沙东公司 Pcsk9拮抗剂
US8093222B2 (en) 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
EP2142217B1 (de) * 2007-03-27 2014-11-05 Merck Sharp & Dohme Corp. Verfahren zum nachweis von automatisch aufbereitetem sezerniertem pcsk9
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
EP2209896B1 (de) 2007-10-26 2017-03-01 Dynavax Technologies Corporation Verfahren und zusammensetzungen zur hemmung von immunantworten und autoimmunität
CN101932728B (zh) * 2007-11-30 2013-06-19 西门子医疗保健诊断公司 脂连蛋白受体片段和使用方法
AR070315A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
AR070316A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
US8748115B2 (en) 2008-12-12 2014-06-10 Merck Sharp & Dohme Corp. PCSK9 immunoassay
AU2010313381A1 (en) 2009-10-30 2012-04-12 Merck Sharp & Dohme Corp. AX1 and AX189 PCSK9 antagonists and variants
CN102639150A (zh) 2009-10-30 2012-08-15 默沙东公司 Ax213和ax132 pcsk9拮抗剂和变体
CN103153346A (zh) 2010-06-16 2013-06-12 戴纳瓦克斯技术公司 使用tlr7和/或tlr9抑制剂的治疗方法
AU2011305655B2 (en) 2010-09-22 2015-11-05 Alios Biopharma, Inc. Substituted nucleotide analogs
EP2655607A4 (de) 2010-12-21 2014-05-14 Univ North Carolina Verfahren und zusammensetzungen zur herstellung aktiver vitamin-k-abhängiger proteine
EP2794630A4 (de) 2011-12-22 2015-04-01 Alios Biopharma Inc Substituierte phosphorthioat-nukleotidanaloga
WO2013142124A1 (en) 2012-03-21 2013-09-26 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
US9012427B2 (en) 2012-03-22 2015-04-21 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US9051378B1 (en) 2014-07-15 2015-06-09 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US9682218B2 (en) 2013-12-23 2017-06-20 Carefusion 2200, Inc. Pleurodesis device and method
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
JP7456605B2 (ja) 2016-12-23 2024-03-27 プレジデント アンド フェローズ オブ ハーバード カレッジ Ｐｃｓｋ９の遺伝子編集
JP7247101B2 (ja) 2017-04-03 2023-03-28 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｓｔｅａｐ－１に結合する抗体
EP3641951B1 (de) 2017-06-22 2023-09-20 The Procter & Gamble Company Filme mit einer wasserlöslichen schicht und einer aufgedämpften organischen beschichtung
EP3642383B1 (de) * 2017-06-22 2022-12-21 The Procter & Gamble Company Filme mit einer wasserlöslichen schicht und einer aufgedämpften anorganischen beschichtung

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000004140A1 (en) * 1998-07-15 2000-01-27 Human Genome Sciences, Inc. 71 human secreted proteins
WO2002026931A2 (en) * 2000-09-25 2002-04-04 Human Genome Sciences, Inc. 71 human secreted proteins

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100236393B1 (ko) * 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제
US5858716A (en) * 1997-05-30 1999-01-12 Smithkline Beecham Corporation H2CAA71 polynucleotides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000004140A1 (en) * 1998-07-15 2000-01-27 Human Genome Sciences, Inc. 71 human secreted proteins
WO2002026931A2 (en) * 2000-09-25 2002-04-04 Human Genome Sciences, Inc. 71 human secreted proteins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HSU SHEAU YU ET AL: "Characterization of two LGR genes homologous to gonadotropin and thyrotropin receptors with extracellular leucine-rich repeats and a G protein-coupled, seven-transmembrane region", MOLECULAR ENDOCRINOLOGY, vol. 12, no. 12, December 1998 (1998-12-01), pages 1830 - 1845, XP002528150, ISSN: 0888-8809 *
LOH E D ET AL: "Molecular Characterization of a Novel Glycoprotein Hormone G-Protein-Coupled Receptor", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 282, no. 3, 6 April 2001 (2001-04-06), pages 757 - 764, XP003002810, ISSN: 0006-291X *

Also Published As

Publication number Publication date
WO2003038063A3 (en) 2003-12-11
WO2002090526A2 (en) 2002-11-14
AU2002326293A1 (en) 2003-01-02
WO2003004622A2 (en) 2003-01-16
WO2003038063A2 (en) 2003-05-08
WO2002095010A2 (en) 2002-11-28
AU2002324424A1 (en) 2002-12-03
AU2002354719A1 (en) 2003-01-21
WO2002102994A2 (en) 2002-12-27
CA2441416A1 (en) 2003-01-16
WO2002076488A1 (en) 2002-10-03
AU2002363296A1 (en) 2003-05-12
WO2002102993A2 (en) 2002-12-27
EP1390390A4 (de) 2009-07-08
EP1423134A2 (de) 2004-06-02
EP1379132A4 (de) 2009-07-01
EP1379264A1 (de) 2004-01-14
WO2002090526A3 (en) 2003-10-30
WO2002102994A3 (en) 2003-07-24
AU2002332391A1 (en) 2003-01-02
AU2002320013A1 (en) 2002-11-18
EP1381622A2 (de) 2004-01-21
WO2002102993A3 (en) 2004-03-25
EP1390390A2 (de) 2004-02-25
CA2441702A1 (en) 2002-12-27
EP1379264A4 (de) 2009-07-08
CA2441840A1 (en) 2002-11-28
WO2002095010A3 (en) 2004-02-12
CA2441755A1 (en) 2003-05-08
CA2441417A1 (en) 2002-11-14
EP1414845A2 (de) 2004-05-06
EP1379132A2 (de) 2004-01-14
EP1404702A4 (de) 2009-07-08
CA2441397A1 (en) 2002-10-03
WO2003004622A3 (en) 2004-02-19
CA2441832A1 (en) 2002-12-27
EP1404702A2 (de) 2004-04-07

Similar Documents

Publication Publication Date Title
EP1379132A4 (de) Sezernierte humanproteine
EP1408759A4 (de) Sezernierte humanproteine
EP1251863A4 (de) 22 sezernierte humane proteine
AU2002361452A8 (en) Secreted proteins
GB0218205D0 (en) Human ZZAP1 protein
IL162598A0 (en) Secreted protein
AU2002232596A1 (en) Secreted human proteins
AU2002354803A8 (en) Secreted proteins
EP1368468A4 (de) Menschliche sezernierte proteine
AU2003301843A8 (en) 157 human secreted proteins
EP1385977A4 (de) Sezernierte proteine
AU2001294719A1 (en) Secreted human proteins
EP1370651A4 (de) 70 humane sekretierte proteines
EP1417224A4 (de) Sekretierte proteine
AU2002365153A1 (en) 41 human secreted proteins
EP1404807A4 (de) 20 sezernierte humanproteine
AU2002246998A1 (en) 50 human secreted proteins
AU2002348034A8 (en) 16 human secreted proteins
AU2002254275A1 (en) Human secreted proteins
AU2002303843A8 (en) Secreted proteins
AU2003211136A8 (en) 6 human secreted proteins
AU2002332483A1 (en) 13 human secreted proteins
AU2002253985A1 (en) 83 human secreted proteins
AU2002247189A1 (en) 70 human secreted proteins
EP1443818A4 (de) Neue sezernierte proteine und ihre anwendungen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20031021

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIC1 Information provided on ipc code assigned before grant

Ipc: C07H 21/02 20060101ALI20090527BHEP

Ipc: C07K 1/00 20060101AFI20040317BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20090605

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090915